Open Access<p>Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review</p>
Author(s) -
Yizhou Peng,
Meng Li,
Xuemei Hu,
Zhiqiang Han,
Zhenya Hong
Publication year - 2020
Publication title -
infection and drug resistance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 39
ISSN - 1178-6973
DOI - 10.2147/idr.s267997
Subject(s) - myelofibrosis , ruxolitinib , medicine , constitutional symptoms , discontinuation , tuberculosis , pediatrics , pathology , bone marrow , disease
The selective Janus-activated kinase inhibitor ruxolitinib (rux) is now widely used to treat myelofibrosis and polycythemia vera due to its remarkable effect of reducing splenomegaly and improving constitutional symptoms. With opportunistic infections secondary to rux constantly reported; however, an increasing number of studies have begun to investigate the mechanism and underlying immunosuppressive effect of rux.